

FOR IMMEDIATE RELEASE

NuSep Investor Presentations

Sydney, Australia 20th December 2010 - NuSep (ASX: NSP) wishes to advise the market that it has made the following Investor Presentations.

****ENDS****

For more information please contact:

Contact:
Prakash Patel
Company Secretary
+61 2 8197 3377
prakash.patel@nusep.com

Released through: Fergus Ross, Six Degrees Investor Communication: +61 420 980 448

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteolQ software enabling NuSep to offer a total Proteomics solution from **Fraction to Function**. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

-  **Gels** – NuSep manufactures and sells precast gels including the innovative **nUView** Gels, which can be visualised 2 minutes after use.
-  **Separation Instruments** – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2008 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF and is expected to undergo clinical trials later this year.
-  **Proteomics Software** – NuSep offers the unique ProteolQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
-  **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

About SingaPharm

SingaPharm is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. SingaPharm is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). SingaPharm's process is based on the **P**reparative **I**solation by **M**embrane **E**lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is 'electronically' driven membrane fractionation.

This process is flexible and modular compared with the large scale inflexible processing facilities of existing fractionators in US and Europe. The process has increased product yield relative to the existing process with increased product safety. The flexible nature of the PrIME technology also provides SingaPharm with access to plasma volumes that previously did not meet the criteria for larger scale processing facilities. Further, SingaPharm's process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

Investor Presentation

December 2010

Sydney and Melbourne



DISCLAIMER

- This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell NuSep securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on information or opinions contained in this presentation and subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.
- To the fullest extent permitted by law, NuSep and its affiliates and their respective officers, directors, employees and agents, accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim and liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this.



Our Vision

**To be the Premier Technology Supplier
in the BioSeparations Market**



Experts in protein discovery



Our Goals

- **Make an Operational Profit of \$1.8m in the 30 June 2011 financial year**
- **Achieve greater than 10% market share of the markets we address**
- **Achieve \$100m in sales and \$20m in net profit within 5 years (eg via the SingaPharm investment)**
- **To become an ASX 300 Company**



NuSep Achievements in 2010

- **Maiden Profit**
- **Debt Free**
- **Very Healthy Balance Sheet**
- **Acquisition of BioInquire**
- **New Business Investments (SingaPharm)**



Experts in protein discovery



Product Pipeline

- **Launch of new Gel products – New products address additional \$48m market.**




- **Launch of new ProteolQ products – Establishing ProteolQ as Mass Spec analysis standard.**



SpermSep Update

- Australian IVF Market \$110m
- New SpermSep Cartridge Patent lodged
- Further Clinical trials to be started in the year
- Applications in the veterinary field:
 - Studs and endangered species
 - IVF application in Animals –
Preliminary laboratory studies in the separation of healthy cattle sperm have shown positive results (Collaboration with University of Sydney)



SingaPharm



MINING LIQUID GOLD

SingaPharm Pte Limited is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. SingaPharm's process is based on the **Preparative Isolation by Membrane Electrophoresis (PrIME)** technology. PrIME provides disposable modular processing that is 'electrically' driven as opposed to 'pressure' driven membrane fractionation. This process is flexible and modular compared with the large scale inflexible processing facilities of existing fractionators in US and Europe. The process has increased product yield relative to the existing processes with increased product safety. Further, SingaPharm's process can produce multiple plasma products in hours compared to days required by the current manufacturers.

Entering blood fractionation market through the SingaPharm investment

- Enter \$US10B blood plasma market with investment in Singapore based SingaPharm
- Cornerstone investor secured - S\$3 million invested in SingaPharm
- NuSep invested S\$4m
- SingaPharm is developing 'mini mill' blood plasma processing plant targeting \$1 billion Asian market
- SingaPharm focussing on niche markets in blood plasma sector not targeted by major blood plasma companies
- Short term clinical trial process – 18 months to first sales



About SingaPharm

- Singapore based biotech company that has developed a disposable plasma processing procedure - *Operated by NuSep*
- Headquartered at Admirax facility, Sembawang
- SingaPharm process can produce multiple plasma products in hours compared to days by current manufacturers



5 PrIME Units



Experts in protein discovery



The Blood Plasma market

- \$US10 billion market worldwide, Dominated by 5 manufacturers
- SingaPharm is focused on the \$US1billion Asian market, **NO ASEAN manufacturer**
- Major manufacturers cannot target smaller Asian markets:
 - Minimum 10,000L batch size
 - Regulator bans on plasma in some Asian countries

SingaPharm is not competing with the major manufacturers. It is focused on a niche market - targeting Asian markets that want to this strategic asset.



Business Plan: SingaPharm

SingaPharm will:

- Buy license to NuSep's **PrIME*** technology for S\$9.5m to manufacture plasma proteins for South East Asia, India and China
- Process small batches of plasma for ASEAN, India and China through mini mill concept.
- Have long term manufacturing contracts to supply Singapore and regional markets
- Increase the safety of plasma products with ability to process plasma from ASEAN in Singapore. Currently plasma from these countries cannot be processed by large fractionators.

** PrIME - Preparative Isolation by Membrane Electrophoresis*



Experts in protein discovery



SingaPharm Mini Mill Concept

- Disposable modular concept manufacturing volumes from 20L to 100,000L
- **HALVES** existing cost of blood plasma by **DOUBLING** the yield
DOUBLING PROFIT
- Singapore Health Sciences Authority approval **will validate NSP PrIME** technology which can then be licensed throughout the rest of the world.



Mini Mill Concept Targets \$1B Asian Plasma Market

- Singapore will be the hub with satellite facilities in ASEAN, India and China



Key Advantages of Mini Mill Concept

	SingaPharm	Current Fractionators
Volume	Any Volume	10,000L and more
Yield	+ 90%	+ 45%
Plant Cost	S \$12M	S \$100M
Processing	12 hours	5 days
Cleaning	Disposable	CIP Required. Increased process time and costs



PrIME Advantage

	PrIME Product	Therapeutic IVIG
Source material	plasma	plasma
Purity	> 99 %	> 99 %
Recovery	>85 %	~40%
PPV removal	> 4 log	> 8 log
Endotoxin removal	>99 %	>99 %
Prion removal BLD*	✓	?

**BLD – Below Limit of Detection

** 8 log removal is achieved by two viral clearance steps, each of which demonstrated greater than 4 log removal




PrIME Benefits

- **Improved product safety through**
 - Viral reduction
 - Prion reduction
 - Pyrogen reduction
 - S/D and PrIME integration
- **No contact between plasma and production equipment eliminates CIP**
- **Complimentary technology with current techniques**
- **Compatible with chromatography polishing**



A short time frame to first sales



SingaPharm Budgeted P&L

	2011 S\$M	2012 S\$M	2013 S\$M	2014 S\$M	2015 S\$M	2016 S\$M	2017 S\$M
Sales	-	-	\$4.75	\$11.5	\$24.5	\$32.7	\$36
Gross Profit	(\$0.5)	(\$0.3)	\$3.3	\$8.3	\$17.6	\$23.9	\$26.4
EBITD A	(\$2.7)	(\$2.8)	\$1.0	\$5.5	\$14.8	\$21	\$23.5
NPAT	(\$2.8)	(\$3)	\$0.5	\$4.9	\$11.8	\$16.9	\$19

Budget is in Singapore dollars. 1 S\$ = A\$.76





Experts in protein discovery

